Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PharmVar GeneFocus: CYP2C19
Mariana Rodrigues Botton, Michelle Whirl‐Carrillo, Andria L. Del Tredici, et al.
Clinical Pharmacology & Therapeutics (2020) Vol. 109, Iss. 2, pp. 352-366
Open Access | Times Cited: 101

Showing 1-25 of 101 citing articles:

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
Craig R. Lee, Jasmine A. Luzum, Katrin Sangkuhl, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 112, Iss. 5, pp. 959-967
Open Access | Times Cited: 286
PharmVar GeneFocus: CYP2B6
Zeruesenay Desta, Ahmed El‐Boraie, Li Gong, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 110, Iss. 1, pp. 82-97
Open Access | Times Cited: 214
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants
Chad A. Bousman, James M. Stevenson, Laura B. Ramsey, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 1, pp. 51-68
Open Access | Times Cited: 175
Review and Consensus on Pharmacogenomic Testing in Psychiatry
Chad A. Bousman, Susanne Bengesser, Katherine J. Aitchison, et al.
Pharmacopsychiatry (2020) Vol. 54, Iss. 01, pp. 5-17
Open Access | Times Cited: 148
Comprehensive genetic diagnosis of tandem repeat expansion disorders with programmable targeted nanopore sequencing
Igor Stevanovski, Sanjog R. Chintalaphani, Hasindu Gamaarachchi, et al.
Science Advances (2022) Vol. 8, Iss. 9
Open Access | Times Cited: 123
Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation
Andrea Gaedigk, Scott T. Casey, Michelle Whirl‐Carrillo, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 110, Iss. 3, pp. 542-545
Open Access | Times Cited: 106
PharmVar GeneFocus: SLCO1B1
Laura B. Ramsey, Li Gong, Seung‐been Lee, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 113, Iss. 4, pp. 782-793
Open Access | Times Cited: 38
DEEPCYPs: A deep learning platform for enhanced cytochrome P450 activity prediction
Daiqiao Ai, Hanxuan Cai, Jiajia Wei, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 25
CYP2C19 Genotype‐Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure
Kayla R. Tunehag, Ashton F. Pearce, Layna P. Fox, et al.
Clinical and Translational Science (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 1
PharmVar GeneFocus: CYP2C9
Katrin Sangkuhl, Karla Claudio‐Campos, Larisa H. Cavallari, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 110, Iss. 3, pp. 662-676
Open Access | Times Cited: 55
A Novel CYP2C‐Haplotype Associated With Ultrarapid Metabolism of Escitalopram
Line Skute Bråten, Tore Haslemo, Marin M. Jukić, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 110, Iss. 3, pp. 786-793
Closed Access | Times Cited: 43
CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis
Andrea Gaedigk, Erin C. Boone, Steven E. Scherer, et al.
Journal of Molecular Diagnostics (2022) Vol. 24, Iss. 4, pp. 337-350
Open Access | Times Cited: 36
Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG)
Marwan K. Tayeh, Andrea Gaedigk, Matthew P. Goetz, et al.
Genetics in Medicine (2022) Vol. 24, Iss. 4, pp. 759-768
Open Access | Times Cited: 36
PharmVar GeneFocus: CYP3A5
Cristina Rodríguez‐Antona, Jessica Savieo, Volker M. Lauschke, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 112, Iss. 6, pp. 1159-1171
Open Access | Times Cited: 29
Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program
Christina L. Aquilante, Katy E. Trinkley, Yee Ming Lee, et al.
American Journal of Health-System Pharmacy (2024) Vol. 81, Iss. 12, pp. 555-562
Closed Access | Times Cited: 6
Pharmacogenetics of Antiplatelet Therapy
Matteo Castrichini, Jasmine A. Luzum, Naveen L. Pereira
The Annual Review of Pharmacology and Toxicology (2022) Vol. 63, Iss. 1, pp. 211-229
Open Access | Times Cited: 22
Frequencies of pharmacogenomic alleles across biogeographic groups in a large-scale biobank
Binglan Li, Katrin Sangkuhl, Ryan Whaley, et al.
The American Journal of Human Genetics (2023) Vol. 110, Iss. 10, pp. 1628-1647
Open Access | Times Cited: 15
Unlocking Genetic Profiles with a Programmable DNA‐Powered Decoding Circuit
Junlan Liu, Chao Zhang, Jinxing Song, et al.
Advanced Science (2023) Vol. 10, Iss. 20
Open Access | Times Cited: 14
From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice
Qamar Shubbar, Aminah Alchakee, Khaled Walid Issa, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Pharmacogenomic Study of SARS-CoV-2 Treatments: Identifying Polymorphisms Associated with Treatment Response in COVID-19 Patients
Alex Serra-Llovich, Natàlia Cullell, Olalla Maroñas, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 553-553
Open Access
Discovery of ancestry-specific variants associated with clopidogrel response among Caribbean Hispanics
Guang Yang, Pablo González, Mariangeli Moneró, et al.
npj Genomic Medicine (2025) Vol. 10, Iss. 1
Open Access
Optimizing proton-pump inhibitor therapy in paediatric eosinophilic esophagitis through CYP2C19 pharmacogenetic testing
Sierra Scodellaro, Karin Bortolin, Margaret Marcon, et al.
Journal of the Canadian Association of Gastroenterology (2025)
Open Access
Pharmacogenetics ofP2Y12receptor inhibitors
Cameron D. Thomas, Alexis K. Williams, Craig R. Lee, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2023) Vol. 43, Iss. 2, pp. 158-175
Open Access | Times Cited: 12
Chitosan and HPMCAS double-coating as protective systems for alginate microparticles loaded with Ctx(Ile21)-Ha antimicrobial peptide to prevent intestinal infections
Cesar Augusto Roque‐Borda, Mauro de Mesquita Souza Saraiva, Wagner Costa Macedo, et al.
Biomaterials (2022) Vol. 293, pp. 121978-121978
Closed Access | Times Cited: 18
Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms
Chaozhuang Shen, Hongyi Yang, Wenxin Shao, et al.
Pharmaceutical Research (2024) Vol. 41, Iss. 4, pp. 731-749
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top